| SPI Energy (NASDAQ: SPI) Launches Hemp/CBD Business and Partners with Navajo Nation |
| |
|
SPI Energy (NASDAQ: SPI), a global provider of photovoltaic (“PV”) solutions for business, residential, government and utility customers and investors, launched its newly established hemp and CBD business.
Why It Matters: The Company has recently executed a management services agreement with the Native American Agricultural Company (“NAAC”) to cultivate hemp in the Navajo Nation; and obtained licenses from the Navajo Nation to engage in lab testing, cultivation, processing, wholesale distribution, and retail sales of hemp. Currently, its hemp cultivation in the Navajo Nation is being overseen by a third-party management company on a 36-acre plot of land licensed by the NAAC. The Company expects to harvest its first crop of hemp in November 2019.
Key Quote: “We are eager to enter the hemp market and happy to be working with the Navajo Nation. Some estimates have the global industrial hemp market growing from $4.4 billion in 2018 to close to $15 billion by 2026. We want to be part of that growth. The Navajo Nation and Native American Agricultural Company are excellent partners for us as we embark on this exciting venture.” — Xiaofeng Peng, CEO
The Backstory: SPI is an established green energy player with global operations in key markets in Australia, Europe, Japan, and the United States. It is leveraging its sizable solar platform and industry expertise to make strategic investment opportunities in green industries with significant growth and earnings potential and/or industries than can benefit from green power.
Disclosure
SPI Energy (NASDAQ: SPI) is a client of RedChip Companies, Inc. SPI agreed to pay RedChip Companies, Inc. 5,000 shares of Rule 144 stock and a monthly cash fee for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Paringa Resources (NASDAQ: PNRL) Appoints Experienced Operations Executive |
| |
|
Paringa Resources (NASDAQ: PNRL), which operates the low-cost, high-quality Poplar Grove coal mine in western Kentucky, announced the appointment of Jim Middleton as Executive Advisor to Paringa Resources Board. Middleton is tasked with providing guidance to assist in further developing safe, efficient, reliable, and cost effective mine operations, specifically at the Company’s Poplar Grove mine.
Why It Matters: Middleton is an experienced underground mining executive with a long and successful history of running coal mining operations for major natural resource companies, including Glencore, BHP, Xstrata, Exxon Coal, and Allied. A mining engineer with 30+ years of coal mining experience, Middleton’s track record of developing, transforming and managing low cost, high productivity underground coal mines, including BHP’s Illawarra deep underground coal complex, will be a great asset to PNRL moving forward.
The Backstory: PNRL operates the low cost, high quality Poplar Grove Mine, part of the Buck Creek Complex located in the Illinois Coal Basin in western Kentucky. The Buck Creek Complex includes two thermal coal mines: (1) the operating Poplar Grove Mine with production capacity ramping up to 2.8 Mtpa; and (2) the permitted Cypress Mine with planned production capacity of 3.8 Mtpa. Construction of the Poplar Grove Mine has been completed and production ramp-up is underway. The Company also has plans to develop the Cypress Mine. Western Kentucky is one of the world’s best mining jurisdictions due to its access to low cost power, utilities, transportation and a non-union labor pool. Mining conditions at Poplar Grove are similar to those in neighboring mines, which rank as some of the world’s most productive room-and-pillar operations.
Disclosure
Paringa Resources Ltd. (NASDAQ: PNRL) is a client of RedChip Companies, Inc. PNRL agreed to pay RedChip Companies, Inc., a monthly cash fee for RedChip investor awareness services.
|
|
| |
|
| Can-Fite Biopharma (NYSE American: CANF) Presents New Data on Treatment of Advanced Liver Cancer |
| |
|
Dr. Michael Silverman, Medical Director of Can-Fite Biopharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver, and inflammatory diseases, delivered a presentation of new data on the treatment of advanced liver cancer with Namodenoson (preparing to file for Phase 3 trial) at the International Liver Cancer Association (ILCA) annual conference.
Why It Matters: While the Company’s Phase II study did not achieve its primary endpoint of overall survival in the whole population (n=78), superiority in overall survival was found in the largest study subpopulation of patients who were classified Child Pugh B7 (CPB7, n=56) based on severity of the underlying cirrhosis, as compared to the placebo treated group. The Phase III study protocol which has already been designed by the Company will include CPB7 patients and will be presented to the FDA in a scheduled End of Phase II Meeting.
Key Quote: “These results attest to the robustness of Namodenoson activity in treating liver cancer. We have designed the Phase III trial to focus on the CPB7 subpopulation, and we look forward to meeting with the FDA soon to present the protocol and move forward with patient recruitment.” — Dr. Michael Silverman, Medical Director
The Backstory: CANF is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease, and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis and its liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. FDA. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (NYSE American: CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a monthly cash fee for 12 months of RedChip investor awareness services and consulting services. RedChip Companies also owns 16,500 shares of CANF Rule 144 stock, acquired in August 2019.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) and MetLife Stadium Enter into Multi-Year Video Solutions Agreement |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures, and markets advanced video recording products for law enforcement, emergency management, fleet safety, and security, announced a three-year contract with MetLife Stadium in East Rutherford, NJ, to provide MetLife Stadium security personnel with FirstVu HD body-worn cameras and back-end software management for all events hosted at MetLife Stadium.
Why It Matters: DGLY will provide a video solution that includes deployment of its patented FirstVu HD body-worn cameras, training and support, along with maintenance and video management. The body-worn cameras will capture video and audio of conversations between security and fans with the goal being de-escalation of situations and evidence falsetto address complaints.
Key Quote: “We are excited to continue our relationship with MetLife Stadium. Our unique product line provides stadiums and entertainment venues with increased accountability and transparency for both fans and staff members.” – Stan Ross, CEO
The Backstory: The three-year agreement comes after several successful deployments of DGLY’s body-worn cameras at MetLife Stadium. Stadium staff has been impressed with the usability of the hardware and back-end software, according to Danny DeLorenzi, Vice President, Security and Safety Services for MetLife Stadium. The goal of this initiative is to provide stadium staff with an extra tool when interacting with fans to create an overall better game day experience for everyone.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| GSRX Industries (OTCQB: GSRX) Reports Record Q2 Revenue of $3.4 Million |
| |
|
GSRX Industries (OTCQB: GSRX), a majority owned subsidiary of Chemesis International (CSE: CSI), filed its second quarter financials with the SEC last week, reporting revenue of $3.4 million for the period, up 20% from the first quarter of 2019 and up more than 800% over prior year results.
Why It Matters: GSRX operational results show significant growth in revenues while maintaining tight control over its operational spending. This growth was primarily achieved through its retail business’ in Puerto Rico, California, Texas, and Tennessee. GSRX currently operates six dispensaries and two retail CBD stores, and has five pre-qualified dispensaries in Puerto Rico that are in various stages of development. It also has a dispensary in Palm Springs, California.
The Backstory: Chemesis is a vertically integrated global leader in the cannabis industry, currently operating within California, Puerto Rico, and Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products.
On Monday, Chemesis announced GSRX received state-wide manufacturing and distribution licenses for its Facility in Point Arena, California. The Northern California facility will allow Chemesis to supply dispensaries throughout the state with high-quality finished goods.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Immuron to Host Investor Conference Call this Thursday, September 26 at 4 pm ET |
| |
|
Learn about Immuron’s expanding development pipeline, revenue growth, and recent developments on an exclusive call with CEO Dr. Gary Jacob this Thursday, September 26, at 4 pm ET. Dr. Jacob will give a 15-minute presentation and then the call will be opened to questions from the audience.
Call information:
Sept. 26 at 4 pm ET /1 pm PT
Conference Line: (866) 821-0302**
**U.S. only. Contact us at info@redchip.com for dial-in info for investors outside U.S.
The Background: IMRN is an Australian biopharma focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The Company currently markets Travelan in Australia, Canada, and the U.S. IMRN’s lead clinical drug candidate, IMM-124E, is presently in Phase II trials in severe alcoholic hepatitis (ASH) and pediatric non-alcoholic fatty liver disease (NAFLD), and the Company recently announced plans to pursue clinical development of IMM-124E through a formal FDA registration pathway as a drug to specifically prevent travelers’ diarrhea. IMRN’s second clinical-stage asset, IMM-529, targets Clostridium difficile infections (CDI), and is presently in a clinical trial in CDI patients. The Company is expected to file an IND with the FDA in the near-term targeting treatment of recurrent CDI.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Look at what you can afford to lose, it’s a numbers game."
-Buzz Heidkte, Owner MidSouth Investor Fund |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
